Amyris (NASDAQ: AMRS) Stock Falls 28% after Operational Issues Result in Lower Production Targets

Free Amyris Claim Evaluation

First Name*
Last Name*
Suffix:
Phone
Email*
State of Residence*
Please tell us about your claim and the number of shares purchased. If you reside outside of USA, note your country here: (max: 5000 Characters)
Select YES if you agree.*
The submission of information to Milberg LLP or one of its attorneys does not create, and the receipt of it does not constitute, an attorney-client relationship. This website presents general information about, among other things, Milberg LLP, currently pending lawsuits, and on-going investigations, which is not intended to be legal advice, nor should you consider it as such. Please do not send confidential or sensitive information and/or documents to anyone at the Firm until you have been notified that a formal attorney-client relationship has been established. Contacting Milberg LLP does not, and should not, limit you in any way from seeking legal advice regarding this or any other matter. By submitting this form, you agree that Milberg LLP may contact you about this or other potential matters of interest to investors and consumers.

Amyris Inc. (NASDAQ: AMRS) is a California-based renewable energy company focusing on one molecule called farnesene, or Biofene, and its derivatives for sale in a range of specialty chemical applications within the following six markets: cosmetics, lubricants, flavors and fragrances, polymers, consumer products, and transportation fuels.

On February 22, 2011, Amyris issued a press release announcing that it had successfully completed multiple runs of its fermentation process using Amyris engineered yeast to produce Biofene. The press release went on to state that “Amyris expects to commence commercial production of Biofene in the second quarter of 2011 and ramp production through manufacturing arrangements with entities including Biomin and Tate & Lyle.” Amyris said it will operate the production facility at Biomin and expects to begin Biofene production in May 2011.

On February 9, 2012, Amyris executives hosted a “Business Update” call for analysts stating that the company no longer planned to complete expansion of its Biomin facility due to operational issues. As a result, Amyris rescinded its previous production targets for Biofene and cash flow projections for 2012. Specifically, the company said it can “no longer adhere to our previously announced plan to produce 40 million liters to 50 million liters of Biofene in 2012.”

In reaction to the news, shares of Amyris fell 28% to $6.99 per share.

Chief Executive Officer John G. Melo said, “we had a significant number of operational issues through 2012, I am sorry, 2011. We ended December with stable operations at Biomin.”

If you would like to learn more about this potential matter, please fill out the form on the right or contact the following attorney:

Andrei Rado, Esq.
Milberg LLP
One Pennsylvania Plaza, 49th Fl.
New York, NY 10119-0165
Phone number: (800) 320-5081
Email: contactus@milberg.com

Milberg LLP has been representing consumers and investors for more than four decades and serves as lead counsel in federal and state courts throughout the United States.

Attorney Advertising.
Prior Results Do Not Guarantee A Similar Outcome.